Cabot (NYSE:CBT) Posts Earnings Results, Misses Expectations By $0.02 EPS

Cabot (NYSE:CBT) announced its quarterly earnings data on Monday. The specialty chemicals company reported $1.70 EPS for the quarter, missing analysts’ consensus estimates of $1.72 by ($0.02), Zacks reports. The business had revenue of $899.00 million during the quarter, compared to analysts’ expectations of $967.02 million. Cabot had a net margin of 11.14% and a return on equity of 25.68%. Cabot’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.80 EPS. Cabot updated its FY 2026 guidance to 6.000-7.00 EPS.

Cabot Price Performance

CBT stock opened at $65.87 on Tuesday. The stock has a 50-day moving average price of $75.13 and a two-hundred day moving average price of $76.00. Cabot has a 12-month low of $65.40 and a 12-month high of $117.46. The company has a current ratio of 2.13, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company has a market cap of $3.50 billion, a PE ratio of 8.61 and a beta of 0.88.

Analyst Upgrades and Downgrades

CBT has been the subject of a number of recent analyst reports. Mizuho lowered their price objective on Cabot from $90.00 to $88.00 and set an “outperform” rating for the company in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Cabot in a research report on Wednesday, October 8th. Finally, UBS Group set a $82.00 price objective on Cabot and gave the company a “neutral” rating in a research report on Tuesday, August 5th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $85.00.

Insider Transactions at Cabot

In other Cabot news, CEO Sean D. Keohane sold 114,436 shares of the business’s stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $79.28, for a total transaction of $9,072,486.08. Following the completion of the sale, the chief executive officer owned 361,518 shares of the company’s stock, valued at approximately $28,661,147.04. The trade was a 24.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.03% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. lifted its stake in shares of Cabot by 409.0% during the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after purchasing an additional 364 shares in the last quarter. Corient Private Wealth LLC lifted its stake in shares of Cabot by 4.5% during the second quarter. Corient Private Wealth LLC now owns 14,496 shares of the specialty chemicals company’s stock worth $1,087,000 after purchasing an additional 625 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Cabot by 344.3% during the second quarter. EverSource Wealth Advisors LLC now owns 813 shares of the specialty chemicals company’s stock worth $61,000 after purchasing an additional 630 shares in the last quarter. California Public Employees Retirement System lifted its stake in shares of Cabot by 0.9% during the second quarter. California Public Employees Retirement System now owns 100,500 shares of the specialty chemicals company’s stock worth $7,538,000 after purchasing an additional 901 shares in the last quarter. Finally, Lazard Asset Management LLC lifted its stake in shares of Cabot by 2.2% during the second quarter. Lazard Asset Management LLC now owns 43,740 shares of the specialty chemicals company’s stock worth $3,280,000 after purchasing an additional 936 shares in the last quarter. Institutional investors and hedge funds own 93.18% of the company’s stock.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.